knowledge -WSS

knowledge

author：knowledge 2025-09-30 23:06:15 - browse：55

intarcia implant. -- health tech coverage from STAT — The matchstick-sized, implantable device from Intarcia Therapeutics releases a steady, continuous, and low-dose stream of a drug for diabetes. Stuart Isett/Fortune Brainstorm Health

An advisory panel to the Food and Drug Administration unanimously voted against a diabetes implant from Intarcia Therapeutics — a former biotech unicorn that faltered after the FDA rejected said implant not once, but twice.

Intarcia called for the panel meeting because of those two rejections, seeking outside input on the FDA’s decision. FDA then granted Intarcia’s request. The agency is not bound to advisory panel decisions, though it tends to follow their advice.

Intarcia started developing its lead therapy, a small, skinny bar implanted under the skin, for type 2 diabetes patients in 2016. The implant delivers a glucose-controlling medicine called exenatide, a member of the GLP-1 drugs that have taken the diabetes and obesity markets by storm. Intarcia’s implant continuously administers the drug over six months, with the goal of improving patient adherence compared to Eli Lilly and Novo Nordisk’s weekly GLP-1 shots.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Boston Scientific acquires urology company Axonics for $3.7 billion

leisure time

WSS

Ascension's ugly legal battle over care for poor patients in Texas

Idaho college killings: Prosecutors dispute DNA could have been planted at murder scene

More hospitals are billing patients as online messages surge

Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

Life science postdocs should get big pay hike, NIH panel says

UK homeowners get some respite as inflation falls by more than anticipated to a 15

hotspot

knowledge

hotspot

Apple is now the first public company to be valued at $3 trillion

UK homeowners get some respite as inflation falls by more than anticipated to a 15

Malaria cases in Florida and Texas: Here’s what you need to know

A look at other Americans who have crossed into North Korea over the years

Apple is now the first public company to be valued at $3 trillion

House passes resolution saying Israel isn't a 'racist or apartheid state'

Medicare details structure of new drug price negotiation program

Flagship, Pfizer team up in deal worth up to $7 billion

Bright Health sells Medicare Advantage business to Molina

Johnson & Johnson sues to stop Medicare negotiation

focus

Arena BioWorks launches in Cambridge to speed drug discovery

Study suggests new cause of Down syndrome: cells linked to aging

Search resumes for 2 missing children washed away with mom in deadly Pennsylvania flash flood

Study: Hearing aids may slow cognitive decline in those at risk

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

Phoenix breaks record with 19 consecutive days above 110 degrees Fahrenheit

leisure time

hotspot

hotspot

hotspot